A Aralex Aachen research explorer

September 18, 2026 article Open access

Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers

Pharmacological Research

DOI: 10.1016/j.phrs.2026.108471 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 0 stored of 0

References 4

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
2024 Nature Metabolism article Medicine Liver Disease Diagnosis and Treatment Open access cited by 1 patent

263

citations
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
2023 Nature Biotechnology article Medicine Liver Disease Diagnosis and Treatment Open access cited by 1 patent

248

citations
The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis
2024 International Journal of Molecular Sciences article Medicine Liver Disease Diagnosis and Treatment Open access

85

citations
Targeting Activated Hepatic Stellate Cells Using Collagen-Binding Chitosan Nanoparticles for siRNA Delivery to Fibrotic Livers
2020 Pharmaceutics article Biochemistry, Genetics and Molecular Biology RNA Interference and Gene Delivery Open access

40

citations

4 results